ecrin-mdr-crcClinical2006Metastatic colorectal cancerMetastatic Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2519204GreeceAustriaBelgiumItalyFranceGermany11UFT5-FUECRIN MDRCompletedfalseA randomized, open-label phase II studyevaluating the efficacy and safety of FOLFOX-4plus cetuximab versus UFOX plus cetuximab asfirst-line therapy in subjects with metastaticcolorectal cancerPrimary objectives: The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer. Primary endpoints: The primary variable is progression-free survival.2006-11-1525192042006-000685-36